Enhanced radioimmunotherapeutic efficacy of a monoclonal antibody cocktail against SMMC—7721 human hepatocellular carcinoma

The improved tumoricidal effect of the radioantibody mixture (“cocktail”)has been reported recently for the treatment of colon tumor.In the present study,we demonstrated the enhanced radioimmunotherapeutic efficacy of a monoclonal antibody (MAb) cocktail against human hepatocellular carcinoma.Therapeutic efficacy was determined by measuring the change in tumor size over a period,determining the percentage of growth inhibition of each treatment at various times after radioantibody therapy.Radioimmunotherapy of SMMC-7721 human hepatoma xenografts in athymic unde mice with combination of ^131Ilabeled Hepama-1 and ^131 I-labeled 9403 mouse MAbs was more effective than using either Hepeam-1 or 9403 MAb alone The MAb cocktail could target a greater number of hepatoma cells and increase the magnitude of hepatoma cell uptake of radioantibodies.The in vitro results explain the enhanced effect of the MAb cocktail in in vivo model system.     

小鼠frataxin抗体的制备及应用

弗里德赖希共济失调(Friedreich ataxia,FRDA)是一种常染色体隐性遗传性疾病,由frataxin(FXN)第一个内含子中GAA重复扩增导致其表达量减少所致。FXN是一种线粒体蛋白,可以调节细胞中铁的代谢,参与铁硫簇和血红素的合成,去除氧化应激等。前期研究发现FRDA病人受累组织有特异性表达的FXN亚型蛋白。为了检测小鼠不同组织中Fxn亚型蛋白的表达,首先要获得具有高度特异性和灵敏性的小鼠Fxn抗体。利用PCR技术扩增小鼠Fxn基因,通过酶切、连接、转化等常规分子克隆方法构建重组原核表达质粒pET24(+)-mFxn,经转化大肠杆菌BL21(DE3),表达可溶性含有his6标记的融合蛋白。该蛋白不含Fxn氨基端77个氨基酸的信号肽,含有130个氨基酸,理论分子量为14.38 kDa。表达的蛋白经Ni-NTA柱和连续梯度离心纯化,获得目的蛋白作为抗原;免疫新西兰大白兔制备抗血清并用硫酸铵沉淀初步纯化得到多克隆抗体。经Western blotting和免疫荧光分析测试,所获得的抗体能够特异性识别细胞内源Fxn,也可应用于组织的免疫沉淀和免疫荧光。这是首次报道利用鼠源Fxn作为免疫原制备的具有高度特异性和灵敏性的Fxn抗体,为深入研究小鼠frataxin亚型蛋白的存在和功能奠定了基础。     

抗谷胱甘肽S转移酶多克隆抗体的制备及特异性鉴定

目的:制备谷胱甘肽S转移酶(GST)的兔多抗,并鉴定该抗体的特异性。方法:用纯化的GST标签蛋白(纯度>98%)免疫新西兰大白兔,获得GST的兔抗血清,并经HiTrap rProtein A柱纯化获得高效价高特异性的抗体;用间接ELISA法检测抗体效价,Western印迹检测抗体的特异性,并与商业化抗体进行对比。结果:通过免疫法得到了GST的兔多克隆抗体血清,抗体效价达1∶1×106,经rProtein A柱纯化后获得了高效价高特异性的抗体,其高效高特异性已达商业化抗体水平。结论:获得了GST的高效价高特异性的兔多克隆抗体。     

Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis

Glypican-3(GPC3) is a promising tumor marker for hepatocellular carcinoma(HCC) diagnosis with high sensitivity and specificity.The aim of this study was to establish an immunohistochemical detection method for GPC3 using the 7D11 monoclonal antibody(7D11 mAb) and evaluate its application for HCC diagnosis.The feasibility of the 7D11 mAb was evaluated by immunohistochemistry performed on adjacent normal liver and intrahepatic cholangiocarcinoma(ICC) samples,Furthermore,the serum GPC3 levels were evaluated in 40 HCC patients,7 ICC patients and 50 healthy donors.The results showed that GPC3 was expressed in 85% of HCC tissues(34/40),but was undetectable in ICC tissues and adjacent normal tissues.GPC3 was significantly increased in the serum of HCC patients(17/40,42.5%) but was undetectable in the serum of ICC patients(0/7,0%) and healthy donors(0/50,0%).This prospective study evaluated the clinical usefulness of 7D11 mAb for GPC3 detection in HCC patients.In conclusion,the use of 7D11 mAb might be good for GPC3 large-scale applications for clinical diagnosis of HCC.     

人SUMO-3基因原核表达及多克隆抗体制备

构建人SUMO-3基因的原核表达载体pET41a(+)-SUMO-3,表达重组GST-SUMO-3融合蛋白,制备人SUMO-3多克隆抗体。试验结果显示,通过PCR方法从重组质粒pEYFP-SUMO-3中克隆到的SUMO-3 N端93个氨基酸的基因序列与NCBI上提供的序列一致,重组质粒pET41a(+)-SUMO-3构建成功;重组pET41a(+)-SUMO-3在E.coli.BL21 (DE3) pLysS中表达GST-SUMO-3融合蛋白,分子量为44.0 kDa,与预期分子量一致;采用亲和层析纯化融合蛋白GST-SUMO-3并免疫家兔,获得人SUMO-3抗体;Western blot 检测显示该抗体可以特异性识别SUMO-3,ELISA检测结果成阳性,抗体效价约为1: 20000。实验结果为进一步研究人SUMO-3及SUMO第二类家族的功能提供了有用工具。     

Novel tumor-associated antigen of hepatocellular carcinoma defined by monoclonal antibody E4-65

A monoclonal antibody, E4-65, produced by immunizing mice with SMMC-7721 cells, a human hepatocellular carcinoma (HCC) cell line, was used to identify and characterize an unreported HCC-associated antigen. Indirect immunofluorescence studies showed that E4-65 antibody reacted with five out of eight HCC cell lines, but not with 10 non-HCC tumor cell lines or a normal liver cell line. Using immunohistochemical examination, E4-65 antigen was detected on the cell membranes and in the cytoplasm of human liver tumor tissues, but was not found in most other tumors, or normal adult or fetal tissues, except for a weakly positive reaction in tissues of the digestive system. Western blot analysis showed that E4-65 antibody bound to a 45 kDa protein in the human HCC cell line and tissue lysates. Enzyme treatment and lectin blotting did not detect the carbohydrate chain in E4-65 antigen. This HCC-associated protein represents a potentially useful target for diagnoses and immunotherapy of human HCC.     

肝癌特异性鼠源及人源化单链抗体基因的克隆与表达

为探讨肝癌特异性鼠源及其人源化单链抗体基因的表达策略并比较二者的结合能力,在3种载体中分别以融合、分泌及胞内表达的方式进行了研究;对复性后的单链抗体以抗原捕获ELISA法进行检测。结果表明,在3种载体中表达的鼠源及人源化单链抗体都是包含体,诱导物浓度及培养温度不影响表达形式;抗原捕获细胞ELISA表明人源化的单链抗体和鼠源单链抗体有相近的抗原结合能力。结论是:在大肠杆菌中表达的基因工程单链抗体的可溶性可能主要由自身氨基酸一级序列决定;先前的设计所采取的人源化方案没有影响到鼠源抗体的CDRs的天然构象,表达的人源化单链抗体提供了免疫原性评价及临床应用的基础。     

类泛素化修饰蛋白SUMO1的表达纯化及抗体制备

SUMO是近年发现的类泛素化修饰蛋白,可通过异肽键共价连接到靶蛋白上,影响靶蛋白的细胞内定位、稳定性及与其它生物大分子的相互作用. 为研究蛋白质的SUMO化修饰,本文表达并利用亲和层析的方法纯化了重组的人SUMO1,制备了兔抗hSUMO1的多克隆抗体. 经ELISA和免疫印迹检测,获得了灵敏度高、特异性好的抗体,可用于SUMO化修饰靶蛋白的鉴定及SUMO化修饰的生物学功能研究.     

草鱼Ⅲ型呼肠孤病毒NS66抗体制备及应用

[背景]草鱼Ⅲ型呼肠孤病毒(grass carp reovirus,GCRV genotypeⅢ) 104株可导致典型性草鱼出血病,对其编码片段的分析有望为临床免疫学检测提供依据。[目的]研究GCRV104株s6基因节段编码蛋白NS66的可能功能,制备良好的GCRV104株NS66蛋白多克隆抗体并分析其特异性。[方法]PCR方法扩增GCRV104株s6基因片段,并克隆至表达载体pGEX-4T-3,转化到大肠杆菌BL21后用IPTG诱导表达,其产物经SDS-PAGE鉴定分析后,通过纯化获得目的蛋白。然后用纯化的pGEX-4T-3-NS66重组蛋白免疫小鼠,获得Anti pGEX-4T-3-NS66多克隆抗体,Western blot测定抗体效价,Western blotting和间接免疫荧光试验(indirect immunofluorescence assay,IFA)鉴定抗体特异性。[结果]SDS-PAGE分析显示表达的重组蛋白约66 kD,大小与预期相符,主要存在于包涵体中;Western blotting测得制备的多克隆抗体效价大于1:50 000,Western blotting和IFA结果表明,制备的多克隆抗体能特异性识别GCRV104病毒。[结论]GCRV104病毒编码的非结构蛋白NS66可能参与了复制和组装过程,形成病毒包涵体,这为建立GCRV104免疫诊断方法及研究GCRV编码的NS66蛋白的功能奠定了前期基础。     

Propofol-induced miR-219-5p inhibits growth and invasion of hepatocellular carcinoma through suppression of GPC3-mediated Wnt/β-catenin signalling activation

Propofol is one of the most extensively used intravenous anaesthetic agents, which has been found to improve the surgical intervention outcome of several types of cancer, including hepatocellular carcinoma (HCC). Additionally, in vitro and in vivo experiments have also indicated that propofol affects the biological behaviour of HCC. However, the underlying mechanisms of the surgical resection of HCC with propofol have not been fully understood. In the present study, we aimed to investigate the underlying mechanism of propofol inhibition of the growth and invasion of HCC cells. Our results showed that treatment with propofol suppressed the proliferation, invasion and migration of HCC in vitro. The subcutaneous xenograft tumour and orthotopic xenograft tumour experiments in nude mice showed that propofol significantly decreased tumour volumes, growth rates and the liver orthotopic xenograft tumour in vivo. Furthermore, the underlying mechanism investigations of the suppressive effects of propofol on HCC cells revealed that propofol treatment upregulated the expression levels of the candidate tumour suppressor miR-219-5p. Silencing of propofol-induced miR-219-5p using anti-miR-219-5p abrogated the inhibitory effects on the proliferation, migration and invasion of HCC cells exerted by propofol treatment. Additionally, we demonstrated that propofol reversed the epithelial-mesenchymal transition of Huh7 and SMMC7721 cells via miR-219-5p induction. The molecular mechanism behind these findings is that propofol-induced miR-219-5p inhibits HCC cell progression by targeting glypican-3 and subsequently results in the inhibition of Wnt/β-catenin signalling. Taken together, our study provides new insights into the advantages of the surgical intervention of HCC with propofol anaesthetization.     

靶向磷脂酰肌醇蛋白聚糖-3治疗肝细胞癌的临床应用前景

磷脂酰肌醇蛋白聚糖-3（glypican-3, GPC3）是一种锚附着在细胞膜表面的癌胚蛋白质, 在肝细胞癌中过表达。GPC3可以作为肝细胞癌的生物标志物, 肝癌病人的血清GPC3水平对于预后评估存在重要价值。此外, 肝癌细胞中GPC3具有免疫反应性, 可以作为治疗靶点, 有关靶向GPC3治疗肝细胞癌的临床试验已经展开。本文简述了GPC3的结构及其在肝细胞癌发生发展中的作用, 回顾了靶向GPC3治疗肝细胞癌的临床研究结果, 并总结了GPC3相关临床应用的最新进展：新的抗GPC3抗体正在研发, 它们与其它靶向药物联用的临床试验正在展开;有关GPC3靶向的TRAB、GPC3疫苗和GPC3基于嵌合抗原受体(CAR)-T疗法的研究正在进行。我们认为,靶向GPC3治疗肝细胞癌的方案具有广阔的临床应用前景, 期待更多的研究聚焦于此, 为靶向GPC3疗法提供更充分的科学依据。     

抗GPC3单链抗体的制备及其在肝细胞癌靶向检测中的应用

磷脂酰肌醇蛋白聚糖3 (Glypican-3,GPC3)是Glypican家族的关键成员,它在肝细胞癌(HCC)的发展、血管生成和转移中起着重要作用。大多数HCC过表达GPC3,而在正常的成人肝脏和良性肝脏病变中几乎检测不到GPC3,因此其可以作为HCC高度特异性的诊断标志和理想的治疗靶标。文中将前期筛选得到的靶向GPC3的单克隆抗体1B11轻重链基因通过柔性肽(Linker)连接,经原核表达纯化,成功获得抗GPC3单链抗体1B11-scFv。通过蛋白印迹法鉴定验证了单链抗体的表达和装配正确;流式细胞术检测其与GPC3阳性细胞株具有与全长抗体相当的结合活性;将单链抗体与近红外荧光探针Cy5.5-NHS偶联,发现其在荷瘤裸鼠体内可精准靶向肿瘤部位,提示其具有实现探针引导下的多方位肝癌精准手术导航的潜力。     

肺炎链球菌SpxA蛋白的原核表达、纯化及多克隆抗体的制备

目的 构建肺炎链球菌SpxA蛋白的原核表达系统,制备其多克隆抗体.方法 设计引物,利用PCR技术扩增肺炎链球菌D39菌株的spxA基因,并插入表达载体pET-28a（＋）内,测序鉴定.重组质粒转化至大肠埃希菌BL21（DE3）中,以IPTG诱导表达含6个组氨酸标签的SpxA重组蛋白,经Ni-NTA亲和层析柱纯化后,以其为抗原免疫BALB/c小鼠制备多克隆抗体.用ELISA及Western印迹方法分别检测多克隆抗体的效价及特异性.结果 从大肠埃希菌中诱导出高表达的SpxA重组蛋白,纯化后免疫小鼠获得抗血清,ELISA测定其效价可达1：2 560 000以上,Western印迹结果显示其能特异性地作用于肺炎链球菌SpxA.结论 成功构建了pET-28a（＋）-spxA原核表达质粒,获得了高纯度的目的 蛋白和高滴度、高特异性的多克隆抗体.     

PDGF-B免疫原的制备及其腹水抗体对HepG2细胞增殖的影响

观察利用融合表达载体pET28-Trx合成的人血小板源性生长因子B(Human platelet-derived growth factor B,h PDGF-B)免疫原的免疫原性,及其诱导小鼠产生针对h PDGF-B的腹水抗体对人HepG2细胞增殖的抑制作用。本研究首先选择hPDGF-B的第103–118及152–167氨基酸序列作为抗原表位,构建p ET28-Trx-重组原核表达载体,表达并纯化获得6×his Trx-h PDGF-BΔ103-118及6×his Trx-h PDGF-BΔ152-167重组蛋白;然后使用纯化后的重组蛋白免疫小鼠,并给予腹腔注射H22肿瘤细胞制备腹水抗体,ELISA法检测抗体滴度,Western blotting法检测纯化腹水抗体与膜结合的PDGF-B结合能力;最后通过CCK8实验检测外源性PDGF-BB和两种纯化腹水抗体对肝癌Hep G2细胞增殖的作用。研究发现上述两种重组蛋白作为免疫原均可诱导小鼠产生高滴度的PDGF-B中和性抗体;两种h PDGF-B纯化腹水抗体能明显抑制PDGF-BB对肝癌Hep G2细胞增殖的促进作用。结果提示,Trx-PDGF-B重组蛋白作为免疫原有望为PDGF-B疫苗的制备提供新的方法,也为临床上肝癌的治疗提供了一种新的思路。     

GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay

Hepatocellular carcinoma (HCC), the most common primary liver cancer has a high mortality in China, and it is usually diagnosed at a late stage, thereby leaving patients with few effective treatment options. Chimeric antigen receptor-T (CAR-T) cell therapy, a novel immunotherapy that has shown promising results in leukemia, lymphoma and multiple myeloma, is also expected to work well in solid tumors, including HCC. However, the ideal therapeutic efficacy has not yet been achieved, in part due to tumor antigen escape caused by antigen heterogeneity. To overcome such challenge, we screened a panel of biomarkers in HCC cell lines and found that GPC3 and B7H3 were highly expressed on HCC with expression heterogeneity. Then we developed a novel bispecific T cell engagers CAR-T (CAR.T-BiTEs) that drives the expression of a CAR specific for GPC3 and BiTEs against CD3 and B7H3, herein referred to as “GPC3-BiTE CAR.” We found that BiTEs promoted the increased activation of untransduced T cells and IFN-γ release. Moreover, BiTEs secreted by GPC3-BiTE CAR-HEK293T cells promoted increased cytotoxicity activity of untransduced T cells against GPC3+/B7H3+ (GPC3 positive/B7H3 positive) and GPC3-/B7H3+(GPC3 negative/B7H3 positive) HCC cell lines. In vitro function assays showed that GPC3-BiTE CAR-T cells exhibited greater cytotoxicity activity against GPC3+/B7H3+ HCC cell lines than GPC3 CAR-T cells (GPC3-targeted CAR-T cells) and B7H3 CAR-T cells (B7H3-targeted CAR-T cells). Furthermore, GPC3-BiTE CAR-T cells exhibited superior cytotoxicity against GPC3 negative HCC cell lines compared with GPC3 CAR T cells. In conclusion, our study showed that GPC3-BiTE CAR T cells exhibited superior antitumor activity than single-target CAR-T cells and can overcome tumor escape induced by antigen heterogeneity, suggesting that this could be a promising therapeutic strategy for HCC.     

抗人Elp3 的N末端抗体制备及在染色质免疫沉淀中的应用

人 Elp3（human elongator protein 3, hElp3）具有组蛋白乙酰转移酶活性,是与延伸中的 RNA 聚合酶Ⅱ结合的 elongator 复合物的催化亚基,可参与组蛋白的乙酰化修饰与基因的转录延伸. Elp3 及其复合物功能异常与人类多种疾病相关. 为运用染色质免疫沉淀等手段深入研究 Elp3 功能,PCR 法克隆 pYES2-hElp3 质粒中编码 hElp3的N端亲水区段（1～69 氨基酸残基）,构建原核表达载体 pMXB10-hElp3-210,经 IPTG 诱导和几丁质柱纯化后,免疫兔制备多克隆抗体. ELISA 检测显示,该抗体有较高的效价(不低于1∶2　500).免疫印迹实验结果表明,该抗体可与纯化的及 HeLa 细胞中的 hElp3 蛋白特异性结合.运用该抗体对转入 elp3Δ菌株的人 Elp3 的染色质免疫沉淀实验结果表明,人 Elp3 可参与酵母 SSA3 基因的转录调控,这可能是人Elp3 能够部分补偿酵母 SSA3 基因延迟表达缺陷的原因.     

苦荞黄酮-3-羟化酶截短体的原核表达与多克隆抗体制备

为了制备苦荞黄酮-3-羟化酶的多克隆抗体,该研究以苦荞种子灌浆期cDNA文库中获得的苦荞黄酮-3-羟化酶基因截短体(truncated Flavanone-3-hydroxylase,TrF3 H)序列为基础,采用PCR扩增F3 H的截短序列编码区(TrF3 H),构建了原核表达载体pET47b-TrF3 H,并转化入大肠杆菌Rosetta(DE3)plysS中进行诱导表达,将经钴离子螯合层析柱纯化后的目的蛋白切胶回收后制备了高效价的多克隆抗体。结果表明:pET47b-TrF3 H在大肠杆菌Rosetta(DE3)plysS中以包涵体的形式高效表达。蛋白质印迹显示,制备的多克隆抗体能特异识别其对应的抗原,天然的黄酮-3-羟化酶蛋白在苦荞的未成熟种子中大量表达。原核表达体系的建立和多克隆抗体的制备为进一步探讨F3H在苦荞中功能奠定了基础。     

木薯14-3-3蛋白家族成员MeGRF3基因的原核表达及多克隆抗体制备

14-3-3蛋白是植物体内重要的信号转导调节分子,在碳代谢、逆境胁迫响应、生长发育等过程中发挥重要调控作用。为了深入解析14-3-3蛋白家族在木薯中的生物学功能,该研究采用酶切连接方法构建木薯14-3-3蛋白家族成员MeGRF3的原核表达载体,用热激法转化大肠杆菌Rosetta(DE3)株系,诱导表达带有MeGRF3的融合蛋白;使用纯化后的MeGRF3融合蛋白免疫新西兰公兔制备多克隆抗体,并检测抗体的效价和特异性。结果显示:(1)成功构建了木薯MeGRF3的原核表达载体pET-30a-MeGRF3,并诱导表达得到带有MeGRF3和6个His标签的融合蛋白。(2)MeGRF3融合蛋白主要以包涵体的形式存在,相对分子质量约为33 kD。(3)间接酶联免疫吸附法(enzyme-linked immunosorbent assay,ELISA)测定的抗体效价为1024000。(4)Western blot分析显示,木薯叶片、茎尖、茎皮和块根中均检测到与MeGRF3蛋白大小一致的条带,说明MeGRF3在这4个组织器官中均表达,但主要是在茎尖和块根中大量积累,表明该研究成功制备的MeGRF3多克隆抗体的特异性较好。     

Proteomic identification of Ku70/Ku80 autoantigen recognized by monoclonal antibody against hepatocellular carcinoma

A murine monoclonal antibody (mAb), CLD3 (IgG(1),kappa), was generated against hepatocellular carcinoma (HCC). Both immunofluorescence and immunohistochemical assays indicated the reactivity of CLD3 mAb localized at the nucleus and/or cytoplasm of tumorigenic HCC cell lines as well as in liver cancer tissues. By immunoprecipitation and using the matrix-assisted laser desorption/ionization-time of flight mass spectrometry approach, the antigenic specificity of CLD3 was determined to be heterodimeric Ku70 and Ku80 autoantigen, which was confirmed by Western blotting.